000			03801nam a2200289Ia 4500
005			20250223033152.0
008			231030s9999 xx 000 0 und d
049			_aDeposit
082			_a616.992
097			_aPh.D
099			_aCai01.19.02.Ph.D.2022.Ha.I
100			_aHany Kamal Shehata Soliman,
245			_aIn vitro study on the possible target therapy for severe acute respiratory syndrome-corona virus-2 isolated from cancer patients / _cBy Hany Kamal Shehata Soliman ; Under the supervision of Abdel-Rhaman Nabawi Zekri, Mohammed Mahmoud Hafez.
246			_aدراسة معملية للعالج المستهدف المحتمل لمتالزمة االلتهاب التنفسي الحاد الشديد - فيروس كورونا 2- المعزول من مرضي السرطان
260			_c2022.
502			_aThesis (Ph.D)-Cairo University,2022.
504			_aBibliography: p. 82-94.
520			_aBackground: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) considers the major global health disaster in 2019-20. Globally, until now, there have highest percentage of viral inhibition and were the most promising drugs against SARS-CoV-2. This study encourages us to continue studying to conduct more clinical trials to test the viral inhibition of these drugs on cancer patients who receives these drugs. been approximately 600 million confirmed cases of COVID-19, with more than 6 million deaths and approximately 570 million recovered. Egypt has approximately 515,000 confirmed cases with 24613 deaths. Till now, there are no targeted therapies for COVID-19. Hence, the drug repurposing strategy of the existing drug may provide a successful outcome for COVID-19 patients with low cost and fast return. Aim of the work: This thesis aims to reveal the variants of SARS CoV-2 and their mutations found in Egypt and to study the action of some available drug compounds on SARS-CoV-2 proteins’ active site through in silico study and to investigate the antiviral effect of these drug compounds using in vitro study. Methods: SARS COV-2 positive samples with high titer were sequenced using Next Generation sequencing to identify the viral variants in Egypt. Then, Homology modeling of viral proteins was performed using modeller software. After that, Docking of our studied drugs versus viral proteins was achieved using Schrodinger software. Cytotoxicity of all materials was studied on VERO E6 cells using an MTT assay. Finally, the antiviral activities of the studied drugs were assessed using plaque assay. Results: Sequencing analysis showed that genomic strains found in Egypt are similar to isolates from England, Brazil, and South Africa. Molecular Docking analysis of the in-silico study revealed binding affinity scores with Mpro, N, Mpro, N, and M of -6.9±0.7Kcal/mol, -7.0Kcal/mol, -7.2±1.0Kcal/mol, -6.7Kcal/mol and - 5.6Kcal/mol for Clofazimine, Tolvaptan, Idelalisib, Olaparib, Ponatinib respectively. In vitro study showed that both Tolvaptan and Clofazimine had the highest percentage of viral inhibition by 73% and 61%, respectively. Conclusion: Most Egyptian genomic strains sequenced are similar to isolates from England, Brazil, and South Africa. This data demonstrated the relative increase of the B.1.1.1 lineages over the B.1. In Egyptian samples, a new clade 20B was discovered using the next strain nomenclature. All studied compounds displayed antiviral activity against SARS-CoV-2 in VERO E6 cell lines. Both Tolvaptan and Clofazimin had the
650			_aCancer Biology
700			_aMohammed Mahmoud Hafez
856			_uhttp://172.23.153.220/th.pdf
905			_aMohamady
942			_cTH _2ddc
999			_c165209 _d165209
336			_2rda content _atext
337			_2rdamedia _aUnmediated
338			_2rdacarrier _avolume